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Introduction
TNF-related apoptosis-inducing ligand (TRAIL), a cytotoxic   
ligand of the TNF family, is a promising anticancer agent 
(Huang and Sheikh, 2007; Mérino et al., 2007; Fulda, 2009). 
TRAIL induces cell death in a wide range of human cancers   
independently of their p53 status without apparent toxic side   
effects in normal tissues. Furthermore, recent studies demon-
strated that TRAIL and other death ligands, including CD95/
FasL and TNF, could sensitize tumor cells for ionizing radiation- 
and drug-induced apoptosis. Such a combined modality may 
circumvent the resistance of tumors against chemo- and radio-
therapy (Marini and Belka, 2003; Schmelz et al., 2004; Marini 
et al., 2005; Fulda, 2009; Newsom-Davis et al., 2009; for review 
see Daniel et al., 2001). Ligands of the TNF family initiate the 
extrinsic  apoptotic  pathway  through  binding  to  cell  surface 
death receptors of the TNF receptor superfamily. Engagement 
of the death receptors leads to receptor oligomerization and the 
formation of the death-inducing signaling complex followed by 
activation of the initiator caspase-8 (Dhein et al., 1992; Muzio 
et al., 1996). In so-called type I cells, active caspase-8 initi-
ates sufficient processing and concomitant activation of the 
downstream effector caspase-3 that ultimately leads to execu-
tion of apoptosis (Scaffidi et al., 1998).
In  contrast,  in  type  II  cells,  the  amount  of  caspase-3   
activated via caspase-8 is not sufficient to trigger apoptosis. In 
such cells, death receptor–mediated apoptosis requires ampli-
fication of the death signal through activation of the intrinsic 
(mitochondrial) cell death pathway (for reviews see Daniel et al., 
2001; Kaufmann and Steensma, 2005). Proteins of the Bcl-2 
family, which comprises anti- and proapoptotic proteins, tightly 
regulate this mitochondrial cell death pathway. The antiapo-
ptotic proteins of this family (Bcl-2, Bcl-xL, Mcl-1, Bfl-1/A1, 
and Bcl-w) are characterized by the presence of all four Bcl-2 
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by TRAIL (Deng et al., 2002; LeBlanc et al., 2002; Ravi and 
Bedi, 2002; Theodorakis et al., 2002; von Haefen et al., 2004; 
Wendt et al., 2005). However, the role of Bak in TRAIL-induced 
apoptosis is barely defined. To elucidate the specific role of Bax 
and Bak, we investigated TRAIL-induced cell death in HCT116 
cells deficient of Bax, Bak, or both. First, to clarify that HCT116 
cells are type II cells, we analyzed how knockdown of caspase-8 
or Bid by siRNAs affected apoptosis induced by TRAIL. Induc-
tion of apoptosis was analyzed by flow cytometric measurement 
of genomic DNA fragmentation, and apoptotic cells were iden-
tified as cells with a hypodiploid, i.e., sub-G1, DNA content. 
Caspase-8 and Bid expression were specifically down-regulated 
by the respective siRNA but not by a control siRNA (Fig. 1 A, 
left). This down-regulation resulted in strong inhibition of 
TRAIL-induced  apoptosis.  Despite  TRAIL  treatment,  only 
8% of caspase-8 knockdown cells and 13% of Bid knockdown 
cells showed a hypodiploid DNA content compared with 33% 
of control cells (Fig. 1 A, right). This indicates that in the ab-
sence of Bid, caspase-8 is not sufficient to initiate execution of 
the death signal by TRAIL, and this Bid dependency clearly 
identifies HCT116 cells as type II cells.
Next, we determined how the specific loss of Bax or Bak 
affected TRAIL-induced apoptosis in HCT116 cells. Specific 
loss of protein expression was achieved by knockout of the Bax 
gene (Zhang et al., 2000) and Bak knockdown by short hairpin 
RNA (Theodorakis et al., 2002). The HCT116 wild-type (wt) 
cells and isogenic cell lines devoid of either Bax or Bak expres-
sion alone (termed Bax
 and Bak
, respectively) or both (termed 
Bax
/Bak
) were treated with 50 ng/ml TRAIL for 24 h (Fig. 1 B). 
In wt cells, TRAIL treatment resulted in DNA fragmentation   
in 36% of the cells, whereas Bax-deficient cells were resistant 
to TRAIL-induced DNA fragmentation. Less than 6% of Bax
 
or Bax
/Bak
 cells showed a hypodiploid, i.e., sub-G1, DNA 
content. In sharp contrast to the loss of Bax, Bak deficiency did 
not  confer  resistance  to  TRAIL-induced  apoptosis.  Upon 
TRAIL treatment, 33% of the Bak
 cells showed DNA frag-
mentation, which is comparable with TRAIL-induced cell death 
in wt cells (Fig. 1 B).
Western blot analysis showed that TRAIL treatment is   
accompanied  by  cleavage  of  the  executioner  caspase-3  in 
HCT116. However, in contrast to Bax-proficient cells, cleaved 
caspase-3 is barely detectable in Bax-deficient HCT116 cells 
regardless of whether or not they expressed Bak (Fig. 1 C).
To further address the role of Bax and Bak and of mito-
chondria in TRAIL-induced apoptosis and to confirm that loss 
of Bak does not affect TRAIL-induced mitochondrial apop-
tosis, we determined the release of cytochrome c upon TRAIL 
treatment. Western blot analysis of cytosolic extracts obtained 
at 24 h after treatment showed that TRAIL induces the release 
of cytochrome c in both HCT116 wt and HCT116 Bak
 cells 
but not in Bax-deficient cell lines (Fig. 1 C, bottom).
Altogether, these results establish that at least in TRAIL-
induced apoptosis, Bax and Bak do not exert redundant func-
tions. Although Bak knockdown does not affect TRAIL-induced 
apoptosis, loss of Bax efficiently protects HCT116 cells from 
cell death induced by TRAIL. Furthermore, the presence of 
endogenous Bak does not influence the proportion of cells   
homology (BH) domains. Proapoptotic homologues lack a BH4 
domain and can be further subdivided into two subfamilies. The 
multidomain Bax homologues including Bax, Bak, and Bok/Mtd 
contain BH1–3, whereas the proteins of the BH3-only subfam-
ily, which comprises Bad, Bid, Bim, Puma, Noxa, Nbk/Bik, 
Bmf, and Hrk, only share the BH3 interaction domain (Daniel 
et al., 2003; van Delft and Huang, 2006). The BH3-only pro-
teins are essential initiators of apoptosis, which, upon a specific 
stimulus, activate a conformational switch and induce oligomer-
ization of the executioner proteins Bax and Bak. Activated, Bax, 
and Bak initiate mitochondrial membrane permeabilization and 
thereby induce the release of cytochrome c from the mitochon-
dria into the cytoplasm. There, cytochrome c associates with 
Apaf-1 and caspase-9 to form the apoptosome that serves to 
facilitate autocatalysis and activation of caspase-9, which in 
turn triggers the downstream executioner caspases. Mitochon-
drial amplification of the death receptor signal in type II cells 
is achieved by caspase-8–mediated cleavage of the BH3-only 
protein Bid. The resulting active, truncated Bid (tBid) activates 
Bax, thereby inducing apoptosome and Smac/Diablo-mediated 
caspase activation. Thus, Bcl-2 family members play a critical 
role in modulating TRAIL-mediated cell death in tumor cells.
Interestingly, it has been shown that overexpression of 
Bcl-2, Bcl-xL, or Mcl-1 inhibits TRAIL-induced apoptosis 
(Henson et al., 2003; Taniai et al., 2004; Zhang and Fang, 2005). 
Likewise, Bax deficiency confers TRAIL resistance of cancer 
cells (Deng et al., 2002; LeBlanc et al., 2002; Ravi and Bedi, 
2002; Theodorakis et al., 2002). However, Bax was dispensable 
for TRAIL-induced caspase-8 activation and subsequent cleav-
age of Bid but crucial for the release of cytochrome c and Smac/
Diablo from mitochondria and downstream activation of cas-
pases. In this line, we have shown that the synergistic induction of 
apoptosis by TRAIL and anticancer drugs or ionizing irradi-
ation depends on Bax but not on the homologous Bak (von 
Haefen et al., 2004; Wendt et al., 2005).
In this study, we show that the requirement for Bak in 
TRAIL-induced apoptosis is determined by the antiapoptotic 
Bcl-2 homologue Mcl-1 rather than Bcl-xL, the second major 
endogenous inhibitor of Bak (Willis et al., 2005). We found that 
Bax-deficient, Bak-expressing carcinoma cells were resistant to 
TRAIL-induced apoptosis, and reconstitution of Bax sensitized 
these cells for TRAIL-induced apoptosis. However, down- 
regulation of Mcl-1 sensitized Bak-proficient but not Bak- 
deficient cancer cells for TRAIL-induced apoptosis regardless 
of their Bax expression status. In contrast, knockdown of Bcl-xL 
failed to overcome TRAIL resistance in Bax-deficient cells. As 
Bax is often lost in tumors, inhibition of Mcl-1 rather than   
Bcl-xL represents an opportunity to open the Bak pathway 
and overcome TRAIL resistance.
Results
In  type  II  cells,  death  receptor–mediated  apoptosis  requires   
amplification of the death signal through activation of the intrin-
sic (mitochondrial) cell death pathway. Several studies indicate 
that Bax is crucial for TRAIL-mediated apoptosis in these cells 
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undergoing TRAIL-induced apoptosis, regardless of whether or 
not they express Bax.
This indicates that, in contrast to Bax, Bak is not activated 
during TRAIL-induced apoptosis and fails to mediate the death 
signal by TRAIL. Bak is mainly inhibited by the antiapoptotic 
Bcl-2 family members Bcl-xL and Mcl-1 (Willis et al., 2005). To 
functionally address the contribution of Mcl-1 in Bak inhibi-
tion, we down-regulated Mcl-1 by RNA interference in HCT116 
wt, Bax
, and Bak
 cells. In all three cell lines, Mcl-1 expression 
levels were specifically decreased by Mcl-1 siRNA but not by a 
control siRNA (Fig. 2, A–C, left). This knockdown of Mcl-1 
slightly sensitized HCT116 wt cells for TRAIL-induced apop-
tosis. In HCT116 wt cells treated with a random siRNA, TRAIL 
induced apoptosis in 30% of the cells, whereas Mcl-1 down-
regulation resulted in 38% of the cells undergoing apoptosis 
(Fig. 2 A, right). More importantly, the down-regulation of   
Mcl-1 rendered Bax-deficient HCT116 Bax
 cells, which are 
resistant to TRAIL-induced apoptosis, susceptible for TRAIL-
induced cell death. Compared with 5% of control cells, TRAIL 
induced apoptosis in 28% of the cells after knockdown of 
Mcl-1 (Fig. 2 B, right). In contrast, Mcl-1 down-regulation in 
Bak-negative,  but  Bax-proficient,  HCT116  cells  failed  to   
enhance induction of apoptosis by TRAIL (Fig. 2 C, right).
To corroborate that all death occurs by apoptosis and to 
control viability, we analyzed TRAIL-treated cells after down-
regulation of Mcl-1 by propidium iodide (PI)/annexin V FITC 
staining. As in the case of DNA fragmentation analysis, TRAIL 
induced apoptosis in HCT116 wt and Bak-deficient HCT116 
cells, indicated by the detection of cells positive for phosphatidyl-
serine exposure and negative for PI staining (early apoptotic) 
and detection of annexin V/PI positivity (late apoptotic) cells 
(Fig. S1). In contrast, annexin V–positive cells were hardly 
detectable in the TRAIL-treated HCT116 Bax
 cell line, con-
firming the resistance of this cell line. Also in line with the 
DNA  fragmentation  analysis,  down-regulation  of  Mcl-1 
slightly sensitizes HCT116 wt but not Bak-deficient HCT116 
cells for TRAIL-induced apoptosis. In contrast, knockdown 
of  Mcl-1  in  the  resistant  cell  line  HCT116  Bax
  strongly   
increases the number of early apoptotic and late apoptotic   
cells after TRAIL treatment, up to 25% each (Fig. S1). The   
result  that  Bak-expressing  HCT116  cells  but  not  Bak- 
deficient cells were sensitized indicates that Mcl-1 knockdown 
facilitates TRAIL to induce apoptosis via a specific, Bak- 
dependent pathway.
To further investigate the mechanism of TRAIL resis-
tance in Bax-deficient cells, we analyzed the influence of 
combined Mcl-1 down-regulation and TRAIL treatment on 
the activation of Bak. During apoptosis, Bak undergoes a con-
formational change, leading to the exposure of its N terminus 
that is inaccessible in vital cells. To study Bak activation, we 
performed a flow cytometric immunofluorescence analysis by 
use of a conformation-specific antibody directed against the 
Bak N terminus in Bax-deficient HCT116 cells. In HCT116 
Bax
 cells treated with a control siRNA, TRAIL failed to acti-
vate Bak. In contrast, knockdown of Mcl-1 led to exposure of 
the Bak N terminus, i.e., Bak activation, in 33% of the HCT116 
Bax
 cells (Fig. 2 D).
Figure 1.  Loss of Bax but not Bak impairs TRAIL-induced apoptosis in the 
type II cell line HCT116. (A) Impaired induction of TRAIL-induced apoptosis 
after down-regulation of caspase-8 or Bid revealed that HCT116 cells are 
of type II. (left) To analyze siRNA-mediated down-regulation of Bid and 
caspase-8, HCT116 wt cells were transfected with the respective siRNA 
and cultured for 24 h followed by Western blot analysis for the presence 
of the respective proteins. (right) 24 h after transfection, HCT116 cells 
were treated with 50 ng/ml TRAIL and cultured for an additional 24 h until 
apoptotic DNA fragmentation was determined on a single-cell level by 
flow cytometric measurement of the cellular DNA content. Cells displaying 
a sub-G1, hypodiploid DNA content are considered apoptotic. c, control. 
(B) TRAIL-induced apoptosis is impaired in Bax-deficient cells but not in 
Bak-deficient HCT116 cells. HCT116 wt, Bax
, Bak
, and Bax
/Bak
 cells 
were treated with 50 ng/ml TRAIL and cultured for 48 h. Control cells 
were grown in the absence of TRAIL. Apoptotic DNA fragmentation was 
determined as described in A. (C) Analysis of Bax and Bak expression, 
processing of procaspase-3, and cytochrome c (cyt c) release are shown. 
Cells were treated with TRAIL and cultured until whole cell extracts were 
analyzed. For the detection of cytochrome c release, cytosolic extracts 
were prepared and subjected to Western blot analysis. m, medium. Error 
bars indicate means ± SD from three experiments.JCB • VOLUME 188 • NUMBER 6 • 2010   854
To support the specific role of Bak inhibition by Mcl-1   
in TRAIL-induced apoptosis, we overexpressed the BH3-only 
proteins Nbk and Noxa in HCT116 Bax
 cells. Nbk preferen-
tially binds to Bcl-2 and Bcl-xL but not to Mcl-1. In contrast, 
Noxa shows specificity for Mcl-1 binding. To induce expression 
of Nbk or Noxa, we used a regulable adenoviral vector system 
(Gillissen et al., 2003), and expression of the respective protein 
under “on” condition was confirmed by Western blot analysis 
(Fig. 3 A). After expression of Nbk or Noxa for 14 h, cells were 
treated with TRAIL. Measurement of hypodiploid cells revealed 
that Noxa but not Nbk sensitized for TRAIL-induced apoptosis. 
Upon Nbk expression and TRAIL treatment, <10% of the cells 
became hypodiploid, whereas Noxa expression combined with 
TRAIL treatment induced DNA fragmentation in 25% of the   
cells (Fig. 3 B). This was confirmed by annexin V FITC/PI stain-
ing. Annexin V–positive cells were detected at background   
levels in the TRAIL-treated HCT116 Bax
 cell upon Nbk ex-
pression. In contrast, Noxa expression strongly increased the 
number of early apoptotic and late apoptotic cells after TRAIL 
treatment up to 15% and 21%, respectively (Fig. 3 C).
To confirm the impact of Mcl-1 on Bak in TRAIL-induced 
apoptosis, we investigated the prostate carcinoma cell line 
DU145, which carries a frameshift mutation in the bax gene. 
Consequently, DU145 cells completely lack Bax expression, 
whereas bak is not mutated, and Bak is endogenously expressed 
to a moderate extent (Gillissen et al., 2003). We previously   
established DU145 cells stably reexpressing the Bax- cDNA 
under the control of a cytomegalovirus promoter (von Haefen 
et al., 2002). Despite expression of Bak, Bax-deficient DU145 
mock cells were resistant to TRAIL-induced apoptosis. How-
ever, reconstitution of Bax sensitized these DU145-Bax cells 
for TRAIL-induced apoptosis. After treatment with 100 ng/ml 
TRAIL, only 13% of the Bax-deficient DU145 cells showed 
DNA fragmentation, whereas 40% of the Bax-reexpressing 
DU145 cells were apoptotic (Fig. 4 A, left). To verify whether 
TRAIL-mediated  apoptosis  requires  amplification  via  the   
mitochondrial pathway in DU145 cells, we down-regulated 
caspase-8 and Bid by siRNA and examined induction of apopto-
sis in DU145-Bax cells. Although down-regulation of caspase-8 
was not complete, reduced caspase-8 expression diminished 
TRAIL-induced apoptosis (Fig. 4 A, right). More importantly, 
knockdown  of  Bid  impeded  TRAIL-induced  cell  death  in 
DU145-Bax cells. Only 12% of the cells transfected with Bid 
siRNA  and  treated  with TRAIL  were  detected  as  apoptotic 
compared with 42% of the cells transfected with control siRNA 
(Fig.  4 A,  right). Together  with  the  Bax  dependency,  these   
results clearly establish that DU145 cells are type II cells and 
require the mitochondrial cell death pathway to undergo death 
ligand–triggered  apoptosis.  Furthermore,  these  data  indicate 
that Bak fails to transmit the cell death signal triggered by 
TRAIL in the DU145 system.
To address the question of whether Bak is kept in check 
by Mcl-1 during TRAIL-induced cell death, we down-regulated 
Mcl-1 by RNA interference in DU145 mock and Bax-reexpressing 
DU145-Bax cells. Mcl-1 expression was specifically decreased 
in both cell lines by Mcl-1 siRNA but not by control siRNA 
(Fig. 4, B and C, left). The transfection with Mcl-1 siRNA   
Figure  2.  Silencing  of  Mcl-1  by  RNA  interference  sensitizes  Bak- 
proficient HCT116 cells for TRAIL-induced apoptosis and enables TRAIL to 
activate Bak. HCT116 wt, Bax
, and Bak
 cells were either left untreated 
or were transfected with control (c) or Mcl-1 siRNAs. (A–C, left) After 
24 h, total protein cell extracts were prepared, and down-regulation of 
Mcl-1 was confirmed by Western blot analysis. Mcl-1 down-regulation   
for HCT116 wt, Bax
, and Bak
 cells is shown in A, B, and C, respectively. 
(right) Cells were treated with 50 ng/ml TRAIL, cultured for an addi-
tional 24 h, and harvested, and apoptotic cells were determined by flow   
cytometric measurement of cellular DNA content. Means ± SD from three 
experiments for the respective cell lines as shown in A–C. (D) To ana-
lyze Bak activation upon TRAIL treatment and Mcl-1 down-regulation, 
Bax-deficient HCT116 cells were stained with a conformation-specific 
antibody against the Bak N terminus and analyzed by flow cytometry. 
The percentage of immunostained cells, indicating Bak activation, is 
shown between the markers (representative histograms). (right) Means 
from triplicates ± SD are shown.855 Bak inhibitors in TRAIL resistance • Gillissen et al.
cells, whereas apoptosis was increased in cells with Mcl-1 
down-regulation to 60% (Fig. 4 B, right). More importantly, 
knockdown of Mcl-1 overcame the TRAIL resistance of Bax-
deficient DU145 mock cells. Treatment with 50 ng/ml TRAIL 
induced apoptotic DNA fragmentation in only 8% of the DU145 
mock cells transfected with control siRNA, whereas Mcl-1 
knockdown sensitized for cell death induction by TRAIL. De-
spite Bax deficiency, 39% of the cells became apoptotic (Fig. 4 C, 
right). This indicates that TRAIL induces apoptosis via a Bak-
dependent pathway upon inactivation of Mcl-1.
To  analyze  the  impact  of  Bcl-xL  (the  second  major   
endogenous inhibitor of Bak) on TRAIL resistance, we down-
regulated Bcl-xL by siRNA (Willis et al., 2005). The knockdown 
of Bcl-xL was specific and considerable (Fig. 5, A and B, top). 
In analogy to Mcl-1 knockdown, down-regulation of Bcl-xL 
enhanced apoptosis by TRAIL from 27% in control cells to 
48% in DU145-Bax cells (Fig. 5 A, right). However, in sharp 
contrast  to  Mcl-1  knockdown,  the  Bcl-xL  down-regulation 
failed to overcome TRAIL resistance in Bax-deficient DU145   
cells. Although Bcl-xL expression was efficiently blocked, only 
9% of the cells showed an apoptotic phenotype in response to 
TRAIL treatment (Fig. 5 B, right) compared with 39% after 
Mcl-1 down-regulation (Fig. 4 C, right). Thus, Bcl-xL appears 
to act in the Bax but not the Bak pathway in TRAIL-induced 
apoptosis. This also indicates that Mcl-1, rather than Bcl-xL, is 
the major factor mediating TRAIL resistance in a Bax-deficient 
setting. Moreover, sensitization by Mcl-1 knockdown is spe-
cific and not caused by a generally reduced amount of anti-
apoptotic Bcl-2 proteins.
Analysis of Bak activation by use of a conformation-
specific antibody directed against an activation-induced epitope 
in the Bak N terminus revealed that Bax-deficient DU145 cells 
treated with a control siRNA are resistant to TRAIL. In con-
trast, knockdown of Mcl-1 in addition to TRAIL treatment 
led to exposure of the Bak N terminus, i.e., Bak activation,   
in 44% of the DU145 cells (Fig. 6 A). In agreement with the 
conformational switch of Bak, TRAIL treatment induced a 
strong  clustering  of  EGFP-Bak  after  Mcl-1  knockdown  in 
DU145–EGFP-Bak cells (Fig. 6 B). In contrast, cells treated 
with a control siRNA showed no EGFP-Bak clustering after 
TRAIL treatment.
Given the therapeutic impact of our finding on resistance 
to TRAIL receptor ligation, we next asked whether small mol-
ecules, known to down-regulate Mcl-1 expression, sensitize 
Bax-deficient  DU145  cells  for  TRAIL-induced  apoptosis.   
The multikinase inhibitor sorafenib (Nexavar; BAY43-9006) 
has been shown to induce apoptosis and sensitizes tumor cells 
for chemotherapy coinciding with down-regulation of Mcl-1 
(Dasmahapatra  et  al.,  2007;  Ding  et  al.,  2008; Yang  et  al., 
2008). Therefore, we treated DU145 cells with different con-
centrations of sorafenib. As expected, treatment of DU145 cells 
with sorafenib resulted in a dose-dependent reduction of Mcl-1 
protein expression (Fig. 7 A). When Bax-deficient DU145 
mock cells were exposed to 50 ng/ml TRAIL, apoptotic DNA 
fragmentation was detectable in only 6% of the cells. The addi-
tion of 10 µM sorafenib alone did marginally increase back-
ground apoptosis. However, 10 µM sorafenib overcame TRAIL 
sensitized DU145-Bax cells for TRAIL-induced apoptosis as 
compared with the control siRNA. In detail, DU145-Bax cells 
transfected with control siRNA and treated with 50 ng/ml 
TRAIL showed apoptotic DNA fragmentation in 32% of the 
Figure 3.  Expression of Noxa but not Nbk overcomes TRAIL resistance in 
Bax-deficient HCT116 cells. HCT116 Bak
 cells were transduced with Ad-
mycNbk-tTA or Ad-mycNoxa-tTA and cultured under “off” or “on” condi-
tions. (A) Expression of Nbk and Noxa was confirmed by immunoblotting. 
(B and C) 14 h after induction of expression, cells were treated for an addi-
tional 24 h with TRAIL. Apoptotic cells were determined by flow cytometric 
measurement of cellular DNA content (B) and annexin V/PI staining (C). 
Means ± SD from triplicates are shown in B.JCB • VOLUME 188 • NUMBER 6 • 2010   856
resistance  and  facilitated  apoptosis  in  33%  of  the  cells   
despite Bax deficiency (Fig. 7 B). Similar results were ob-
tained with roscovitine (CYC202 or seliciclib), a small mol-
ecule, cyclin-dependent kinase inhibitor that was also shown 
to down-regulate Mcl-1 (MacCallum et al., 2005; Raje et al., 
2005; Ortiz-Ferrón et al., 2008). Preincubation of DU145 mock 
cells  with  nontoxic  concentrations  of  roscovitine  strongly   
sensitized and efficiently overcame TRAIL resistance of these 
Bax-deficient cells (Fig. 7 C). Down-regulation of Mcl-1 by 
Sorafenib or roscovitine also enhanced cell death induction in 
Bax-expressing DU145-Bax cells upon TRAIL treatment in a 
dose-dependent manner (Fig. S2).
So far, we have shown that knockdown of Mcl-1 but not 
Bcl-xL can sensitize cells for TRAIL-induced apoptosis and 
overcomes TRAIL resistance of Bax deficient cells. To ana-
lyze the role of Mcl-1 and Bcl-xL in the regulation of cell 
death induced by other death receptors, we treated DU145   
wt and DU145-Bax cells with TNF or CD95/FasL. As shown 
in Fig. 8 A (left), DU145-Bax cells are sensitive to TNF- 
induced apoptosis, and sensitivity is increased after down-
regulation  of  Mcl-1  or  Bcl-xL.  DU145-Bax  cells  are  also 
susceptible for CD95/FasL-induced cell death, which is also 
enhanced after Mcl-1 or Bcl-xL knockdown (Fig. 8 A, right). 
In contrast, neither TNF nor CD95/FasL induced an appre-
ciable number of apoptosis in Bax-deficient cells. However, 
this resistance to TNF- and CD95/FasL-induced cell death 
can be overcome by down-regulation of Mcl-1 but not Bcl-xL 
(Fig. 8 B). Collectively, these data show a differential impact 
of the endogenous Bak inhibitors Mcl-1 and Bcl-xL on death 
receptor–induced apoptosis in Bax-deficient cells.
Figure 4.  Mcl-1 knockdown sensitizes type II DU145-Bax cells for TRAIL-
induced apoptosis and overcomes TRAIL resistance in Bax-deficient DU145 
cells. (A, left) DU145 mock or DU145-Bax cells were treated with increas-
ing concentrations of TRAIL and cultured for 24 h. Measurement of apop-
totic  DNA  fragmentation  revealed  that  reexpression  of  Bax  overcomes 
TRAIL resistance of DU145 cells. Open squares, DU145 mock cells; closed 
squares, DU145-Bax cells. (right) To confirm that DU145 cells are type   
II, cells were transfected with control (c), caspase-8, or Bid siRNA and cul-
tured for 24 h. (top) Total cell extracts were prepared, and down-regulation   
of respective proteins was confirmed by Western blot analysis. Black   
lines indicate that intervening lanes have been spliced out. (bottom) 24 h 
after siRNA-mediated knockdown of caspase-8 or Bid, cells were treated 
with 50 ng/ml TRAIL and cultured for an additional 24 h. (right) Cells   
were harvested, and apoptotic cells were determined by flow cytometric 
measurement of cellular DNA content. (B and C) DU145-Bax (B) and DU145 
mock cells (C) were transfected with control or Mcl-1 siRNA and cultured 
for 24 h. Mcl-1 down-regulation and expression status of Bax and Bak 
were confirmed by Western blot analysis. After knockdown of Mcl-1, cells 
were treated with TRAIL at 50 ng/ml and cultured for an additional 24 h. 
Measurement of apoptotic DNA fragmentation revealed that Mcl-1 down-
regulation sensitized DU145-Bax cells for TRAIL-induced apoptosis and 
overcame TRAIL resistance in DU145 mock cells. Error bars indicate means ± 
SD from three experiments.
Figure 5.  Down-regulation of Bcl-xL fails to circumvent TRAIL resistance 
of Bax-deficient DU145 cells. (A and B) DU145-Bax (A) and DU145 mock 
cells (B) were transfected with control (c) siRNA or Bcl-xL siRNA and cul-
tured for 24 h. Down-regulation of Bcl-xL was confirmed by Western blot 
analysis. After knockdown of Bcl-xL, cells were treated with TRAIL at 50 ng/ml 
and cultured for an additional 24 h. Measurement of apoptotic DNA frag-
mentation revealed that Bcl-xL down-regulation sensitized DU145-Bax cells 
for TRAIL-induced apoptosis but failed to circumvent TRAIL resistance of 
DU145 mock. Error bars indicate means ± SD from three experiments.857 Bak inhibitors in TRAIL resistance • Gillissen et al.
Discussion
Despite the fact that TRAIL preferentially induces apoptosis   
in tumor cells, resistance of many cancers toward TRAIL- 
induced apoptosis limits the therapeutic application of this 
death ligand. Apart from loss of TRAIL receptor expression, 
resistance can be acquired by different mechanisms, including 
up-regulation of TRAIL decoy receptors (Mérino et al., 2007), 
increased expression of the caspase-8 inhibitor cFLIP (Krueger 
et al., 2001; Micheau, 2003), loss of caspase-8 (Grotzer et al., 
2000),  or  enhanced AKT  kinase  activity  caused  by  PTEN 
phosphatase deletion (Nesterov et al., 2001). In type II cells, 
which represent the majority of malignancies, TRAIL-mediated 
Apart from the HCT116 and DU145 systems, we ana-
lyzed the impact of Mcl-1 and Bcl-xL on TRAIL-induced 
apoptosis  in  three  additional  cell  lines:  the  osteosarcoma   
cell line U2OS, the cervical cancer cell line HeLa, and the 
colon carcinoma cell line LoVo. It is known that U2OS and 
HeLa cells are resistant to TRAIL-induced apoptosis. West-
ern blot analysis revealed that both cell lines are positive for 
Bax and Bak expression (Fig. S3). Thus, other mechanisms 
than  loss  of  Bax  have  to  account  for  the  insensitivity  to 
TRAIL-induced apoptosis. However, down-regulation of ei-
ther Mcl-1 or Bcl-xL sensitizes these cell lines for TRAIL-
induced apoptosis (Fig. 9, A and B). These data support our 
notion that Mcl-1 and Bcl-xL are involved in the regulation 
of  TRAIL-induced  cell  death  in  Bax/Bak-proficient  cells.   
In contrast, and despite loss of Bax as a result of biallelic 
frame shift mutation (Sturm et al., 2001), LoVo cells are not 
entirely resistant. This might be because of the high expres-
sion level of Bak (Fig. S3). Nevertheless, sensitivity of LoVo 
cells  toward  TRAIL-induced  apoptosis  can  be  increased   
by the down-regulation of Mcl-1 but not Bcl-xL (Fig. 9 C). 
Collectively, these data support our finding that the endoge-
nous inhibitors of Bak, Mcl-1 and Bcl-xL, have a differential 
impact on the Bak pathway in TRAIL resistance of Bax-
  deficient carcinomas.
Figure 6.  Mcl-1 silencing enables TRAIL to activate Bak. 24 h after Mcl-1 
down-regulation, Bax-deficient DU145 cells were treated with 50 ng/ml 
TRAIL and cultured for an additional 24 h. (A) Cells were stained with a 
conformation-specific antibody against the Bak N terminus (NT) and ana-
lyzed by flow cytometry. The percentage of immunostained cells, indicating 
Bak activation, is shown between the markers (representative histograms). 
Means from triplicates ± SD are shown on the right. (B) Clustering of EGFP-
Bak after siRNA repression of Mcl-1 and TRAIL treatment. The distribution of 
EGFP-Bak was determined by fluorescence microscopy. Bar, 50 µm.
Figure 7.  Sorafenib and roscovitine overcome TRAIL resistance in Bax-
negative DU145 cells. (A) Bax-deficient DU145 mock cells were treated 
with different concentrations of sorafenib, and down-regulation of Mcl-1 
but not Bcl-xL was observed upon Western blot analysis. (B and C) DU145 
cells were preincubated with or without the indicated concentrations of 
sorafenib (B) or roscovitine (C), treated with 50 ng/ml TRAIL, and cultured 
for 24 h. Apoptotic cells were detected by flow cytometric measurement of 
cellular DNA content. Means ± SD from three experiments are shown.JCB • VOLUME 188 • NUMBER 6 • 2010   858
cells, induction of cell death by TRAIL is mediated specifi-
cally via an apparently Bak-independent pathway that relies   
in turn entirely on Bax. Evidence for a differential role of Bak 
versus Bax in cell death regulation also comes from analyses   
on BH3-only proteins or bacterial toxins (Cartron et al., 2003b; 
Gillissen et al., 2003, 2007; Lindenboim et al., 2005; Pardo   
et al., 2006).
Interestingly, recent studies have shown involvement of 
Mcl-1,  an  endogenous  Bak  inhibitor,  in  the  regulation  of 
TRAIL-induced apoptosis (Henson et al., 2003; Taniai et al., 
2004; Wirth et al., 2005; Han et al., 2006; Meng et al., 2007). 
Similar data are available for Bcl-xL, the second major endog-
enous inhibitor of Bak (Willis et al., 2005). Therefore, we asked 
whether down-regulation of Bcl-xL or Mcl-1 overcomes the 
failure of TRAIL to trigger the Bak pathway and thereby sensi-
tizes cancer cells for TRAIL-induced apoptosis to bypass the 
TRAIL resistance of Bax-deficient cancer cells. Mcl-1 down-
regulation sensitized Bak-expressing cells for TRAIL-induced 
apoptosis regardless of their Bax status, whereas down-regulation 
of Bcl-xL failed to overcome TRAIL resistance in Bax-deficient 
cells. In contrast to Mcl-1, down-regulation of Bcl-xL failed to 
apoptosis depends on the mitochondrial death pathway. Con-
sequently, deregulation of Bcl-2 family members may also 
contribute to TRAIL resistance (Rudner et al., 2005). Several 
studies have shown that loss of the proapoptotic Bcl-2 family 
member Bax protects cancer cells from apoptosis induced by 
TRAIL (Deng et al., 2002; LeBlanc et al., 2002; Ravi and 
Bedi, 2002; Theodorakis et al., 2002; von Haefen et al., 2004; 
Wendt et al., 2005). This is in line with our results that, despite 
expression of functional Bak (Gillissen et al., 2003, 2007), 
Bax-mutated DU145 cells are resistant to TRAIL-induced 
apoptosis and reexpression of Bax overcomes this resistance. 
Likewise, knockout of Bax renders TRAIL-sensitive HCT116 
tumor cells resistant to TRAIL. Nevertheless, regarding a 
rheostat model of a balance between pro- and antiapoptotic 
Bcl-2 family proteins (Gallenne et al., 2009), it might be that 
loss of Bax protects cells just by decreasing the amount of pro-
apoptotic multi-BH domain proteins under a critical threshold 
necessary for TRAIL to induce apoptosis. In this study, we show 
that in sharp contrast to Bax deficiency, loss of Bak expression 
fails  to  protect  HCT116  colon  cancer  cells  from TRAIL-
  induced apoptosis. This indicates that in human carcinoma 
Figure 8.  Mcl-1 but not Bcl-xL mediates resistance to TNF and CD95/FasL-
induced apoptosis in Bax-deficient DU145 cells. (A and B) DU145-Bax (A) 
and DU145 mock cells (B) were transfected with control, Mcl-1, or Bcl-xL 
siRNA and cultured for 24 h. Down-regulation of Mcl-1 and Bcl-xL was 
confirmed by Western blot analysis. After knockdown of Mcl-1 or Bcl-xL, 
cells were treated with TNF (left) or CD95/FasL (right) and cultured for an 
additional 24 h. Measurement of apoptotic DNA fragmentation revealed 
that Mcl-1 or Bcl-xL down-regulation sensitized DU145-Bax cells for TRAIL-
induced apoptosis. However, only Mcl-1 knockdown overcomes resistance 
of Bax-deficient DU145 cells, whereas Bcl-xL knockdown failed to circum-
vent resistance. Means ± SD from triplicates are shown.
Figure 9.  Different impact of Mcl-1 and Bcl-xL silencing on TRAIL-induced 
apoptosis in Bax-proficient and -deficient cell lines. U2OS, HeLa, and LoVo 
cells were transfected with control (c), Mcl-1, or Bcl-xL siRNA. (left) Down-
regulation of respective proteins was confirmed by Western blot analysis. 
After knockdown of Mcl-1 or Bcl-xL, cells were treated with TRAIL and cul-
tured for an additional 24 h. (right) Measurement of hypodiploid cells 
revealed that Mcl-1 down-regulation sensitized U2OS, HeLa, and LoVo 
cells for TRAIL-induced apoptosis. In contrast, Bcl-xL knockdown sensitized 
only U2OS and HeLa cells (both Bax proficient) but failed to sensitize Bax-
deficient LoVo cells. Means ± SD from triplicates are shown.859 Bak inhibitors in TRAIL resistance • Gillissen et al.
Therefore, small molecules known to down-regulate Mcl-1 
might represent suitable means to overcome TRAIL resistance. 
The kinase inhibitor sorafenib blocks, e.g., NF-B, and thereby   
increases TRAIL-induced apoptosis in a variety of neoplas-
tic human cell lines including human leukemia cells (Meng et al., 
2007; Rosato et al., 2007). Roscovitine induces cell death in multi-
ple myeloma cells by down-regulation of Mcl-1 (MacCallum et al., 
2005; Raje et al., 2005) and sensitizes glioma cells to TRAIL- 
mediated apoptosis. In this study, sorafenib and roscovitine 
circumvent TRAIL resistance in Bax-negative carcinoma cell lines 
and enable TRAIL to activate Bak. However, sensitization of 
DU145 cells by roscovitine is even more powerful than Mcl-1   
down-regulation by siRNA. Thus, other mechanisms might 
be involved in sensitization by roscovitine. In this vein, roscovitine 
was shown to sensitize cancer cells to TRAIL-mediated apoptosis 
by down-regulation of survivin and XIAP (Kim et al., 2004).
In summary, resistance against TRAIL occurring in con-
sequence of Bax deficiency can be overcome by down-regulation 
of Mcl-1, which enables TRAIL to activate a Bak-dependent 
apoptotic pathway (Fig. 10). The model of Bak activation upon 
TRAIL treatment shown in Fig. 10 is based on the derepres-
sion mechanism. However, inactivation of Mcl-1 is a prerequisite 
for Bak activation irrespective of the derepression or the di-
rect activator model. The result that inactivation of Mcl-1 en-
ables TRAIL to activate Bak is an important finding because 
Bax is often mutated in tumors having a microsatellite muta-
tor phenotype, and loss of Bax expression has been associated   
sensitize  Bak-positive/Bax-negative  DU145  cancer  cells, 
showing that sensitization for TRAIL is not caused by a de-
creased amount of antiapoptotic proteins in general but re-
quires specific knockdown of Mcl-1 to allow for the activation 
of the Bak pathway. This is in agreement with the finding that 
down-regulation of Mcl-1 failed to sensitize Bak-deficient/
Bax-positive  HCT116  cells,  indicating  that  in  contrast  to   
Bcl-xL, Mcl-1 is not involved in the regulation of Bax activity 
during TRAIL-mediated apoptosis.
Insights into the mechanism by which TRAIL relies on 
Bax but fails to activate the Bak pathway came from recent pub-
lications, showing that apoptosis relies on selective interactions 
between particular subsets of Bcl-2 proteins. Although contro-
versial models suggest (Cartron et al., 2003a, 2004) or object 
(Uren et al., 2007; Willis et al., 2007) binding of BH3-only pro-
teins to Bax/Bak, interactions between BH3-only proteins or 
multidomain proteins with antiapoptotic Bcl-2 family members   
are well established. Bak binds to Mcl-1 and Bcl-xL but not to 
Bcl-2. Thus, in healthy cells, Bak is specifically held in check 
by Bcl-xL and Mcl-1 (Willis et al., 2005). In addition, Chen et al.   
(2005) suggests that Mcl-1 does not bind with appreciable affinity 
to tBid, the active form of Bid generated through caspase-8–
  mediated cleavage during TRAIL-induced apoptosis. These re-
sults are consistent with other studies showing that tBid is not   
associated  with  Mcl-1  after  TRAIL  treatment  (Meng  et  al., 
2007). This indicates that tBid is not sufficient to release Bak 
from its inhibitory binding to Mcl-1. In contrast, TRAIL caused 
increased binding of Bim and Puma to Mcl-1 (Meng et al., 
2007). Nevertheless, binding of Bim, Puma, or Nbk has been 
shown to stabilize Mcl-1 (Mei et al., 2005; Czabotar et al., 2007; 
Gillissen et al., 2007). Inhibition of proapoptotic Bcl-2 family 
members by Mcl-1 might therefore be further enforced by   
increased expression of Mcl-1 induced by TRAIL through acti-
vation of the NF-B pathway (Ricci et al., 2007) that would also 
facilitate expression of Bcl-xL, an NF-B target. Nevertheless, 
our functional data delineate that Mcl-1 but not Bcl-xL mediates 
inhibition of the Bak pathway as an important mechanism of 
TRAIL resistance in Bax-deficient human carcinoma. Of note,   
this also proves true for TNF- and CD95/FasL-induced apoptosis. 
Bax-deficient DU145 and HCT116 cells are resistant to TNF- 
and CD95/FasL-induced apoptosis, which can be overcome 
by down-regulation of Mcl-1 but not Bcl-xL. Supporting evi-
dence for a differential impact of Mcl-1 and Bcl-xL comes   
from our recent observation that Mcl-1 but not Bcl-xL mediates 
inhibition of the Bak pathway upon the expression of the BH3-
only protein Nbk (Gillissen et al., 2007). Furthermore, Bax- 
deficient DU145 cells are more susceptible for anticancer drug– 
induced apoptosis upon Mcl-1 down-regulation (unpublished 
data). Collectively, these data emphasize the central role of 
Mcl-1 in the regulation of Bak activity upon different death 
stimuli. Finally, inhibition of Mcl-1 upon expression of the BH3-
only protein Noxa sensitizes Bax-deficient cells for TRAIL-
induced apoptosis. Noxa shows specificity for Mcl-1 binding, 
thereby enabling TRAIL to induce killing via Bak. In contrast, 
the BH3-only protein Nbk does not bind to Mcl-1 and fails to 
disrupt the Mcl-1–Bak binding and therefore fails to facili-
tate TRAIL killing via the Bak pathway.
Figure 10.  Model for the regulation of TRAIL-induced apoptosis by Bcl-2   
family members. (A) In healthy cells, Bax is inactivated by Bcl-xL (and Bcl-2),   
whereas Bak is sequestered by Bcl-xL and Mcl-1. (B) Via the caspase-8   
tBid signaling pathway, TRAIL activates the proapoptotic Bax through neu-
tralization of the antiapoptotic Bcl-xL. In contrast, the antiapoptotic Mcl-1, 
which is not targeted by tBid, keeps Bak in check. Down-regulation of   
Mcl-1 by RNA interference or targeted therapeutics, like sorafenib or 
roscovitine, enables TRAIL to activate Bak.JCB • VOLUME 188 • NUMBER 6 • 2010   860
Measurement of apoptotic cell death by flow cytometry
Apoptosis was determined on the single cell level by measuring the DNA 
content of individual cells by flow cytometry as described previously (Gillissen 
et al., 2007). Cellular DNA content was measured with a logarithmic   
amplification in the FL-3 channel of a flow cytometer (FACScan; BD) equipped 
with the CELLQuest software. Data are given in percent hypoploidy (i.e., 
the percentage of cells with a sub-G1 DNA content), which reflects the 
percentage of apoptotic cells with fragmented genomic DNA. Alternatively, 
apoptosis was determined by measuring binding of annexin-V–FITC upon 
exposure of phosphatidyl serines on the cell surface and PI counterstaining 
(Gillissen et al., 2003).
Analysis of Bak clustering
EGFP-Bak  oligomerization  was  determined  by  the  use  of  fluorescence   
microscopy in DU145 cells stably expressing EGFP-Bak. Cells were trans-
fected with Mcl-1 siRNA or control siRNA and after 24 h treated with or 
without 50 ng/ml TRAIL for a further 24 h. Cells were fixed in PBS contain-
ing 4% paraformaldehyde for 15 min, washed twice in PBS, and mounted 
in Aquamount. Mounted cells were inspected at room temperature using a 
microscope (Axiovert 200; Carl Zeiss, Inc.) equipped with a Plan Apochro-
mat 63×/1.4 NA objective lens (Carl Zeiss, Inc.) and a digital camera 
(ORCA ER; Hamamatsu Photonics). Images were acquired using Openlab 
software (PerkinElmer) on a Mac computer (OS X 10.5; Apple, Inc.).
Construction of recombinant adenovirus
The  recombinant  adenovirus  for  Noxa  expression  was  constructed  as   
described previously for Nbk (Gillissen et al., 2003). In brief, the E3 re-
gion of Ad5 was replaced by tTA under the control of a cytomegalovirus 
promoter and an SV40 poly(A) tail. Noxa cDNA was introduced into the 
E1 region under the control of the Tet-off system to achieve conditional   
expression in the absence of doxycycline. The resulting DNA construct was 
transfected in HEK293-packaging cells to produce vector stocks. Adenoviral 
stocks were propagated according to standard procedures described   
previously in Hemmati et al. (2002).
Online supplemental material
Fig. S1 shows sensitization of Bak-proficient HCT116 cells to TRAIL-induced 
phosphatidyl  serine  exposure  upon  down-regulation  of  Mcl-1.  Fig.  S2 
shows sensitization of Bax-proficient DU145 cells to TRAIL-induced apop-
tosis upon sorafenib and roscovitine treatment. Fig. S3 shows Bcl-xL, Mcl-1, 
Bax, and Bak protein expression levels of the cell lines used in this study.   
Online  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.200912070/DC1.
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